Yokomizo T, Nakamura M, Shimizu T. Leukotriene receptors as potential therapeutic targets. J Clin Invest 2018; 128(7): 2691-701.
Zaitsu M, Hamasaki Y, Yamamoto S, Kita M, Hayasaki R, Muro E, et al. Effect of dexamethasone on leukotriene synthesis in DMSO-stimulated HL-60 cell. Prostaglandins Leukot Essent Fatty Acids 1998; 59(6): 385-93.
Jua EM, Leea SE, Hwangb HJ, Kima JH. Antioxidant and anticancer activity of extract from Betula platyphylla var. japonica. Life Sci 2004; 74(8): 1013-26.
Soni KK, Raut N, Lawal TO, Patel U, Mahady GB. A purified fraction of Ocimum tenuiflorum (L.) inhibits LTC4, LTA4 and COX-2 activities, down-regulates mRNA expression in HL-60 cells and reduces lung inflammation in an OVA induced asthma model in BALB/c mice. Immunol Endocr Metab Agents Med Chem 2017; (17): 115-26.
Shah BN, Patel NP, Pandya P. Role of leukotriene in inflammation and anti-leukotriene therapy. J Pharm Res 2008; 1(2): 113-25.
Soni KK, Patel U, Artwolt J, Nunamaker E, Mahady GB. Reduction of OVA-induced lung inflammation in mice treated with Ayurvedic herbs using 2-D and 3-D imaging. Pharm Biol 2012; 50: 564.
Soni KK, Shrivastava PN, Jones T, Mahady JL, Patel U, Mukherjee P, et al. Extracts of Bacopa monnieri (L) Pennell down-regulate the expression of leukotriene C4 synthase mRNA in HL-60 cells and suppress OVA induced inflammation in BALB/c Mice. Curr Bioact Compd 2014. 10: 021-30.
Jain B, Jain VK, Ahirwar D, Ahirwar B. Acute oral toxicity and in vitro leukotriene inhibitory property of hydro-alcoholic extract of Nicotiana tabacum in guinea pig Lung strips. Int J Green Pharm 2018; 12(2): 107-14.
Guimaraes JP, Filgueiras LR, Martins JO, Jancar S. Leukotriene involvement in the insulin receptor pathway and macrophage profiles in muscles from type 1 diabetic mice. Mediat Inflamm 2019; p. 4596127.
Lee DK, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. Systemic bioactivity of intranasal triamcinolone and mometosone in perennial allergic rhinitis 2003. 55: 310-13.
Joseph GA, Yuan G, Cheuk KL. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis. US4663347 (1987).
Edwin SW, Alexander K. Synthetic flavonoidsas inhibitors of leukotrienes and 5-lpoxygenase. US4889941 (1989).
Daines RA, Kingsbury WD, Pendrak I. Benzoic acid derivatives for treating leukotrienerelated diseases. WO9118880 (1991).
Zamboni R, Guay D, Labelle M. Quinoline derivatives as leukotriene ntagonists. WO1993021159 (1993).
Brooks DW, Woods KW, Rodrigues KE. Indole carboxylate derivatives which inhibits leukotriene biosynthesis. WO9412179 (1994).
Cohen N. Substituted pyridine leukotriene B4 antagonists.AU690258 (1995).
Norbert D, Wolfram H, Labaudiniere R. Substituted quinolyl exhibiting selective compound leukotriene B4 antagonist activity.S5492915 (1996).
Gareau Y, Labelle M, Dufresne C, et al. Heteroaryl diol acid as leukotriene antagonists. WO9640638 , (1996).
Fleisch JH, Jackson WT, Sawyer JS. Leukotriene antagonists useful for treating ischemia reperfusion injury. WO9842346 (1998).
Makovec F, Peris W, Rovati LC. Tyrosine derivatives with antileukotriene activity. WO2001058892 (2001).
Rubin PD. Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors. US6509353 (2003).
Liversidge G, Jenkins S, Wertz C, Bosch H. Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations. WO2006099591 (2006).
Maus J, Fyrnys B, Hoffmann T, et al. The combination of anti-cholinergic and leukotriene receptor antagonists for the treatment of respiratory diseases. WO2006097250 (2006).
Arnaiz D, Davey D, Guilford W, et al. Di-amine derivatives as inhibitors of leukotriene A4 hydrolase. WO2007079078 (2007).
Armstrong HM, Change LL, Chu L, Sisco RM. OK, H.O., Xu, J., Ujjainwalla, F. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis. US20090258885 In: (2009).
Armstrong M, Reisdorph NAM, Rabinovitch N. Measurement and analysis of leukotrienes. WO2010045633 (2010).
Gosselin F, Vydra V. Compounds and methods for leukotriene biosynthesis inhibition. US7915298 (2011).
Dominique R, Goodnow RA, Kowalczyk A, Qiao JLQ, Sidduri A, Tilley JW. Leukotriene B4 inhibitors. US8093253 (2012).
Berry A, Chen Z, Lombaert SD, et al. Biarylamide inhibitors of leukotriene production. WO201208281 (2012).
Kim JH, Cho AC, Kim GY, et al. Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancer. US8288357 (2012).
Rathod R, Bhatt T, Joshi K, Dole B, Murty-Kadiyala VNS, Thennati R. Cysteinyl leukotriene antagonists. WO2013051024 (2013).
Taub R, Bortz T, Franc J, et al. Phenylalkyl n-hydroxyurea for treating leukotriene related pathologies. US20130190514 (2013).
Kim JH, Choi JA, Kim EY, et al. Method of treating cancer with antibodies against long-form leukotriene B4 receptor BLT2. US8518889 (2014).
Bylock LA. Benzodioxanes in combination with other actives for inhibiting leukotriene production. WO2013131901 (2014).
Bartolozzi A, Bosanac T, Chen Z, et al. Oxadiazole inhibitors of leukotriene production. US8658661 (2014).
Lombart SD, Liu W, Lo HY, Nemoto PA. Benzimidazole inhibitors of leukotriene production. US8772304 (2014).
Wojciak JM, Dickerson CT, Visentin DB, Sabbadini RA. Compositions and methods for binding Cysteinyl Leukotrienes (CysLTs) for treatment of disease. US20150152172 (2015).
Rubinstein M, Dvash-Riesefeild E. Inhibitors of leukotriene mediated activity for alleviating chemotherapy side effects and stress induced cell death. WO2015125137 (2015).
Heim-Riether A, Padyana AK, Liang S, Taylor SJ, Zhang Q. Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase. US9139567 (2015).
Stack DR. Leukotriene B4 antagonist compound. US9187411 (2015).
Nicolls MR, Tian W, Rajadas J. Treatment of pulmonary hypertension with Leukotrienes inhibitors. US2013025178 (2013).
Maus J, Fyrnys B, Hofmann T, Weingart M, Szelenyl I. The combination of anticholinergic and leukotriene receptor antagonists for the treatment of respiratory diseases. EP1863476 (2016).
Abeywardane A, Brunette SR, Burke MJ, et al. Inhibitors of leukotriene production. US9403830 (2016).
Gosselin J, Gaudreault E. Use of leukotriene B4 in combination with a toll-like receptor legend, a rig-i-like receptor legend, or a nodlike receptor legend to enhance the innate immune response.US20170151204 (2017).
Kim JH. Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. US9772324 (2017).
Rubinstein M, Dvash-Riesefeild E. Inhibitors of leukotrienemediated activity for treating side Orengo, effects of statin therapy.US20180064682 (2018).
Orengo JM, Allinne J, Murphy AJ, Yancopoulo GD. Methods of treating inflammatory conditions. WO2018102597 (2018).
Roinestad K, Guilford W, Kirkland T, Bhatt L, Springman E. Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase. WO2018107158 (2018).
George JT, Emiola A. Leukotriene receptor antagonists and their derivatives for use as antibacterial agents. US20180185332 (2018).
Rockson SG, Nicolls MR, Tian WA, Jiang X, Kim J. LTB4 inhibition to prevent and treat human lymphedema. US20180193296 (2018).
Benison J. Reduction of pro-inflammatory HDL using a leukotriene inhibitor. WO2018152405 (2019)
Bresnick SD. Prophylactic leukotriene inhibitor and implant displacement therapy for prevention and treatment of capsular contracture in silicone breast augmentation. US10179129 (2019).
May BC. Use of levocetirizine and montelukast in the treatment of autoimmune disorders. US10201537 (2019).
Choi Y, Kim JH, Lee K, et al. Novel compound having BLT inhibitory activity and composition,for preventing or treating inflammatory diseases, comprising same as active ingredient. US20190071395
Paiement N, Zerbe HG, Conway JW, Obeid R, Aigner L, Michael J. Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists. US20190133925 (2019).
Roinestad K, Guilford W, Kirkland T, Bhatt L, Springman EB. Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase. US20190161437 (2019).
Amin N, Graham N, Pirozzi G, Teper A. Methods for treating or preventing asthma by administering an IL-4R antagonist.US20190169299 (2019).
Lai Y. Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof. US10315997 (2019)
Springman EB, Pugh MM, Bhatt L, Grosswald R. Methods of inhibiting leukotriene A4 hydrolase. US10350197 (2019).
Sai L, Yanqiu Z, Dongmei C, Yinjun L. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. Trop J Pharm Res 2019; 18(3): 625-30.